ClinicalTrials.gg
CompletedNCT05548556MANOEUVREUpdated Oct 15, 2026

A Study to Evaluate RO7204239 in Participants With Facioscapulohumeral Muscular Dystrophy

A Phase 2 interventional study of Placebo and RO7204239 in Facioscapulohumeral Muscular Dystrophy (FSHD), sponsored by Hoffmann-La Roche. Completed at 9 sites in 4 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-10-15.

Sponsored by Hoffmann-La Roche · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was May 2025, 1 year 6 months ago, and no results have been posted to the registry; the sponsor requested a delay in submitting them in Apr 2026.
Updated Oct 15, 2026Now CompletedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
51
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 32 studies in Muscular Dystrophy, Facioscapulohumeral with a site in United States — 8 open to participants now, 13 under way, 1 of them phase 3. Muscular Dystrophy, Facioscapulohumeral · United States.

Enrollment
11th of 21
51 · median 51
Started
2023
with 1 other
Phase 2
7 of 32
1 open now
Registered
21st of 32
by date

Among the 32 studies in Muscular Dystrophy, Facioscapulohumeral with a site in United States, this one is the 11th largest by enrollment of the 21 interventional ones that give a count, is one of 2 that started in 2023, is one of 7 in phase 2, and was the 21st registered.

Muscular Dystrophy, Facioscapulohumeral

79 studies on the registry are indexed under Muscular Dystrophy, Facioscapulohumeral; 26 are open to participants now.

Browse Muscular Dystrophy, Facioscapulohumeral studies →

Open to participants now

8 of the 32 studies in Muscular Dystrophy, Facioscapulohumeral with a site in United States are open now. Recruiting first, the newest first:

3 more — sign in →

All 8 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 19 Muscular Dystrophy, Facioscapulohumeral studies recruiting now, 9 (47%) set no upper age limit and 9 (47%) stop at 75 or younger; 10 take children under 18; 6 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 32 studies in Muscular Dystrophy, Facioscapulohumeral with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the pharmacodynamics, safety, tolerability, pharmacokinetics, and efficacy of RO7204239, a humanized monoclonal antibody that binds to human latent myostatin, in ambulant adult participants with facioscapulohumeral muscular dystrophy (FSHD).

03

Conditions studied

  • Facioscapulohumeral Muscular Dystrophy (FSHD)
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Genetic confirmation of FSHD1 or FSHD2
  • Clinical findings consistent with FSHD
  • Ability to walk unassisted
  • Ricci Clinical Severity Scale score ≥ 2.5 and ≤ 4
  • Agreement to maintain the same frequency and intensity of physiotherapy, occupational therapy, and other forms of exercise during the clinical study

Exclusion criteria

Exclusion Criteria:

  • Pregnancy or breastfeeding, or intention of becoming pregnant during the study or within 17 months after the final dose of RO7204239
  • Current or previous treatment (or receipt) of anti-myostatin therapies
  • Treatment with any therapy within 90 days prior to screening, or 5 drug-elimination half-lives of the drug, whichever is longer
  • to MRI scans
  • Presence of abnormalities
  • Presence of clinically significant cardiovascular disease
  • Presence of clinically significant abnormal findings in echocardiography at screening, with the exception of mitral valve prolapse, which does not exclude participants from the study
  • Any major illness within 1 month before screening
  • Ascertained or presumptive (e.g., anaphylactic reaction) to RO7204239, or to the constituents of its formulation
  • History of (except in situ basal cell carcinoma of the skin and in situ carcinoma of the cervix of the uterus that have been excised and resolved with documented clean margins on pathology)
  • Any clinically relevant history of anaphylactic reaction requiring inotropic support
  • Any abnormal skin conditions, pigmentation, or lesions in the area intended for SC injection (abdomen) and that would prevent visualization of potential injection-site reactions to RO7204239
  • Immobilization, surgical procedures, fracture, or trauma to the upper or lower limbs within 90 days prior to screening or longer, if judged by the investigator that it may affect motor function assessment
  • Any planned surgery that may affect a participant's motor function assessment, including participants who have had surgery of scapular fixation within the 12 months preceding screening or that are planned during the study
  • Use of the following medications within 90 days prior to enrollment: salbutamol or another β2-adrenergic agonist taken orally; creatine; recombinant human growth hormone; recombinant human insulin growth factor-1; testosterone, oxandrolone, or other anabolic steroid; chronic oral or parenteral use of (inhaled corticosteroid use is allowed) unless required to manage injection reactions;agents anticipated to increase or decrease muscle volume or strength
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
51 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Participants will complete a 4-week pre-treatment period to collect baseline movement data with a wearable device, then receive subcutaneous (SC) placebo every 4 weeks for 52 weeks. After the treatment period, participants will have the option to receive RO7204239 for an additional 52 weeks.

    Drug: Placebo

  • Experimental
    RO7204239

    Participants will complete a 4-week pre-treatment period to collect baseline movement data with a wearable device, then receive SC RO7204239 every 4 weeks for 52 weeks. After the treatment period, participants will have the option to receive RO7204239 for an additional 52 weeks.

    Drug: RO7204239

Interventions

  • DrugPlacebo

    Participants will receive subcutaneous (SC) placebo every 4 weeks (Q4W)

  • Participants will receive SC RO7204239 Q4W

06

What researchers measure

Primary outcomes

  1. Percent change from baseline in contractile muscle volume (CMV) of quadriceps femoris muscles as assessed by magnetic resonance imaging (MRI) bilaterally

    Time frame: Week 52

  2. Percentage of participants with adverse events (AEs)

    Time frame: Up to 2.5 years

Secondary outcomes

  1. Change from baseline in serum concentration of total latent myostatin

    Time frame: Through 2 years

  2. Change from baseline in serum concentration of free latent myostatin

    Time frame: Through 2 years

  3. Change from baseline in serum concentration of mature myostatin

    Time frame: Through 2 years

  4. Percent change from baseline in CMV of 36 muscles based on whole body MRI

    Time frame: Weeks 28 and 52

  5. Change from baseline in fat fraction of 36 muscles based on whole body MRI

    Time frame: Weeks 28 and 52

  6. Percent change from baseline in CMV of quadriceps femoris muscles as assessed by MRI bilaterally

    Time frame: Week 28

  7. Change from baseline in fat fraction of quadriceps femoris muscles as assessed by MRI bilaterally

    Time frame: Weeks 28 and 52

  8. Percent change from baseline in CMV of tibialis anterior muscles as assessed by MRI bilaterally

    Time frame: Weeks 28 and 52

  9. Change from baseline in fat fraction of tibialis anterior muscles as assessed by MRI bilaterally

    Time frame: Weeks 28 and 52

  10. Percent change from baseline in CMV of biceps brachii muscles as assessed by MRI bilaterally

    Time frame: Weeks 28 and 52

  11. Change from baseline in fat fraction of biceps brachii muscles as assessed by MRI bilaterally

    Time frame: Weeks 28 and 52

  12. Percent change from baseline in contractile cross-sectional area (CSA) of skeletal muscle in the proximal lower limb muscles as assessed by MRI bilaterally

    Time frame: Weeks 28 and 52

  13. Change from baseline in fat fraction of proximal lower limb muscles as assessed at a single mid-femur slice bilaterally by MRI

    Time frame: Weeks 28 and 52

  14. Serum concentration of RO7204239

    Time frame: Through 2 years

  15. Maximum serum concentration (Cmax) of RO7204239

    Time frame: Through 2 years

  16. Area under the concentration-time curve (AUC) of RO7204239

    Time frame: Through 2 years

  17. Trough concentration (Ctrough) of RO7204239

    Time frame: Through 2 years

  18. Percentage of participants with anti-drug antibodies (ADAs)

    Time frame: Baseline up to approximately 2 years

07

Study locations

9 sites
  • University of Irvine Medical Center (UCIMC)
    Orange, California 92868, United States
  • Regents of the University of Colorado
    Aurora, Colorado 80045, United States
  • University of Kansas Medical Center
    Fairway, Kansas 66205, United States
  • Kennedy Krieger Institute
    Baltimore, Maryland 21205, United States
  • Rigshospitalet
    København Ø, 2100, Denmark
  • Policlinico Universitario Agostino Gemelli
    Rome, Lazio 00168, Italy
  • Asst Grande Ospedale Metropolitano Niguarda
    Milan, Lombardy 20162, Italy
  • National Hospital for Neurology and Neurosurgery,
    London, WC1N 3BG, United Kingdom
  • Royal Victoria Infirmary
    Newcastle upon Tyne, NE1 4LP, United Kingdom
08

References and documents

Individual participant data

Plan to share: Yes — For eligible studies, qualified researchers may request access to individual patient level clinical data. See Roche's commitment to transparency of clinical study information here: https://go.roche.com/data_sharing

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2023 to primary completion in May 2025, 26 months.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 16, 2022
First posted
Sep 21, 2022
StartActual
Feb 7, 2023
Primary completionActual
May 2, 2025
CompletionActual
Oct 9, 2026
Results delay requested
Apr 24, 2026
Last update
Oct 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Completed
changed Oct 15, 2026
Show all 1 update
  1. Oct 15, 2026
    Active, not recruiting→Completed
    + 2 other changes: verification date and date precision

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05548556
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Sep 21, 2022
Start date
Feb 7, 2023
Primary completion
May 2, 2025
Completion
Oct 9, 2026
Last update
Oct 15, 2026

Study contacts

Clinical Trials
study director · Hoffmann-La Roche

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Emugrobart

Start the discussion